Could Sour Over $3 soon. Acasti Pharma (NASDAQ:ACST) peaked at nearly $3 on two occasions in the last six months. Delaying the CaPre drug data sent the stock to a ~25% drop Dec. 23, 2019. So, when the company posts topline results for the study this month, ACST stock might surge once again.
Source: Shutterstock
Acasti said that the trial results for the Trilogy 1 pivotal Phase 3 trial of CaPre come out this month. It explained that “the reporting of Trilogy 1 was postponed due to an unexpected delay in data processing and transfer from the central testing laboratory to the statistical consultants for independent and external validation.”
Given the holiday period slowing activity, markets did not need to react so negatively. The company, which develops innovative drugs for cardiometabolic diseases, is dependent on strong CaPre results to lift ACST stock. CaPre is a formulation of omega-3 (“OM3”) phospholipid for treating Hypertriglyceridemia (“HTG”).